StockNews.com Begins Coverage on Akari Therapeutics (NASDAQ:AKTX)

StockNews.com assumed coverage on shares of Akari Therapeutics (NASDAQ:AKTX) in a research note issued to investors on Sunday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Akari Therapeutics Stock Up 1.5 %

Shares of NASDAQ AKTX opened at $3.32 on Friday. Akari Therapeutics has a 1 year low of $1.08 and a 1 year high of $4.40. The stock has a fifty day moving average price of $3.62 and a two-hundred day moving average price of $2.57.

Akari Therapeutics Company Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.